James K. Schwarz

2.0k total citations · 1 hit paper
27 papers, 1.4k citations indexed

About

James K. Schwarz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, James K. Schwarz has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in James K. Schwarz's work include Cancer Immunotherapy and Biomarkers (6 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). James K. Schwarz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). James K. Schwarz collaborates with scholars based in United States, Canada and Australia. James K. Schwarz's co-authors include Joseph R. Nevins, D. Gale Johnson, W. Douglas Cress, Stephen H. Devoto, Eric Smith, Srikumar Chellappan, Laszlo Jakoi, Jeffrey Simpson, Peter Brooks and Les Irwig and has published in prestigious journals such as Nature, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

James K. Schwarz

26 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of transcription factor E2F1 induces quiescent cells to enter S phase

1993 845 citations D. Gale Johnson, James K. Schwarz et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James K. Schwarz United States	12	928	866	213	168	154	27	1.4k
Timothy K. MacLachlan United States	22	552 0.6×	1.2k 1.4×	356 1.7×	104 0.6×	187 1.2×	46	1.6k
Meg R. Gerstenblith United States	17	929 1.0×	1.2k 1.4×	213 1.0×	258 1.5×	113 0.7×	35	2.1k
Matthew J. Cecchini Canada	19	491 0.5×	691 0.8×	111 0.5×	96 0.6×	188 1.2×	69	1.3k
Hiroyasu Nagahama Japan	17	697 0.8×	1.0k 1.2×	86 0.4×	281 1.7×	222 1.4×	30	1.8k
Wilma Bergman Netherlands	18	1.1k 1.2×	543 0.6×	212 1.0×	306 1.8×	441 2.9×	44	1.5k
Irina Golovleva Sweden	25	225 0.2×	927 1.1×	284 1.3×	146 0.9×	174 1.1×	78	1.9k
Giovanna Bianchi‐Scarrà Italy	21	711 0.8×	704 0.8×	192 0.9×	229 1.4×	346 2.2×	70	1.4k
Stuart Naylor United Kingdom	23	544 0.6×	952 1.1×	423 2.0×	62 0.4×	163 1.1×	32	1.9k
Paula Aguilera Spain	22	570 0.6×	549 0.6×	125 0.6×	198 1.2×	116 0.8×	84	1.3k
Michael G. Gartside Australia	21	416 0.4×	1.2k 1.4×	117 0.5×	144 0.9×	273 1.8×	38	1.8k

Countries citing papers authored by James K. Schwarz

Since Specialization

Citations

This map shows the geographic impact of James K. Schwarz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James K. Schwarz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James K. Schwarz more than expected).

Fields of papers citing papers by James K. Schwarz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James K. Schwarz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James K. Schwarz. The network helps show where James K. Schwarz may publish in the future.

Co-authorship network of co-authors of James K. Schwarz

This figure shows the co-authorship network connecting the top 25 collaborators of James K. Schwarz. A scholar is included among the top collaborators of James K. Schwarz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James K. Schwarz. James K. Schwarz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reck, Martin, Federico Cappuzzo, Delvys Rodríguez‐Abreu, et al.. (2019). 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours. Annals of Oncology. 30. xi46–xi47. 1 indexed citations

Lin, Chi, Vivek Verma, Audrey J. Lazenby, et al.. (2019). Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. 42(10). 755–760. 18 indexed citations

Lin, Chi, Vivek Verma, Quan P. Ly, et al.. (2018). Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiotherapy and Oncology. 132. 55–62. 24 indexed citations

Vaena, Daniel A., Jorge Chaves, Nicholas J. Vogelzang, et al.. (2018). PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS3115–TPS3115. 3 indexed citations

Dudek, Arkadiusz Z., Li Liu, Ajjai Alva, et al.. (2018). Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.. Journal of Clinical Oncology. 36(15_suppl). 4558–4558. 5 indexed citations

McGuire, Timothy R., et al.. (2015). Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clinical & Experimental Metastasis. 32(2). 111–124. 17 indexed citations

Giri, Smith, Shadi Hamdeh, Vijaya Raj Bhatt, & James K. Schwarz. (2015). Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation. Journal of the National Comprehensive Cancer Network. 13(5). 508–514. 11 indexed citations

Basch, Ethan, Mark C. Scholz, Johann S. de Bono, et al.. (2015). Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology. 33(7_suppl). 141–141. 31 indexed citations

Bhatt, Vijaya Raj, Apar Kishor Ganti, James K. Schwarz, & Jue Wang. (2014). Safety and Efficacy of Preoperative Sorafenib Therapy in Facilitating Cytoreductive Surgery in Renal Cell Carcinoma. Future Oncology. 10(5). 703–706. 3 indexed citations

10.

Wang, Jue, Timothy R. McGuire, James K. Schwarz, Jane L. Meza, & James E. Talmadge. (2012). Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 30(5_suppl). 164–164.

11.

Schwarz, James K., Zdeněk Kořı́stek, Jan Starý, et al.. (2008). [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].. PubMed. 54(7-8). 757–70. 1 indexed citations

12.

Ramnath, Nithya, Jihnhee Yu, Nikhil I. Khushalani, et al.. (2008). Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anti-Cancer Drugs. 19(7). 749–752. 4 indexed citations

13.

Tang, Patricia A., Lillian L. Siu, Eric X. Chen, et al.. (2007). Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 26(3). 257–264. 73 indexed citations

14.

Douglas, Wade G., Nestor Rigual, Joseph E. Bauer, et al.. (2005). Advanced Soft Palate Cancer: The Clinical Importance of the Parapharyngeal Space. Otolaryngology. 133(1). 66–69. 12 indexed citations

15.

Schwarz, James K., et al.. (2004). Organ preservation in patients with squamous cancers of the head and neck. Surgical Oncology Clinics of North America. 13(1). 187–199. 4 indexed citations

16.

Shieh, Sherry, et al.. (2004). Pleural mesothelioma with cutaneous extension to chest wall scars. Journal of Cutaneous Pathology. 31(7). 497–501. 11 indexed citations

17.

Polák, J., Šoňa Peková, James K. Schwarz, Tomáš Kozák, & C Haškovec. (2003). [Expression of cyclin-dependent kinase inhibitors in leukemia].. PubMed. 142(1). 25–8. 2 indexed citations

18.

March, Lyn, et al.. (1994). n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ. 309(6961). 1041–1044. 101 indexed citations

19.

Schwarz, James K., Stephen H. Devoto, Eric Smith, et al.. (1993). Interactions of the p107 and Rb proteins with E2F during the cell proliferation response.. The EMBO Journal. 12(3). 1013–1020. 207 indexed citations

20.

Johnson, D. Gale, James K. Schwarz, W. Douglas Cress, & Joseph R. Nevins. (1993). Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 365(6444). 349–352. 845 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact